Orexo AB Reports Regulatory Approval of Edluar® in Europe

UPPSALA, Sweden--(BUSINESS WIRE)--Regulatory News: Orexo AB (“Orexo”)(STO:ORX) is pleased to report that Edluar® has received regulatory approval in Europe, according to information supplied by Meda AB (“Meda”), Orexo’s global commercial partner for the product. Edluar®, a sublingual formulation of zolpidem, is indicated for treatment of insomnia characterized by difficulties with sleep initiation, and was developed by Orexo using the Company’s proprietary sublingual formulation technologies

Back to news